FibroBiologics, Inc. financial data

Symbol
FBLG on Nasdaq
Industry
Pharmaceutical Preparations
Location
455 E. Medical Center Blvd, Suite 300, Houston, TX
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 82.2 %
Debt-to-equity -1.99K %
Return On Equity 3.15K %
Return On Assets -167 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.7M shares
Weighted Average Number of Shares Outstanding, Basic 33.5M shares +18.7%
Weighted Average Number of Shares Outstanding, Diluted 33.5M shares +18.7%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.92M USD +112%
General and Administrative Expense 8.59M USD +44.4%
Operating Income (Loss) -12.5M USD -63.4%
Nonoperating Income (Expense) 2.85M USD
Net Income (Loss) Attributable to Parent -17.8M USD +77.2%
Earnings Per Share, Basic -0.59 USD/shares +87.5%
Earnings Per Share, Diluted -0.59 USD/shares +87.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 7.83M USD
Other Assets, Current 18K USD
Assets, Current 8.2M USD
Property, Plant and Equipment, Net 772K USD
Operating Lease, Right-of-Use Asset 1.5M USD
Assets 10.5M USD
Contract with Customer, Liability, Current 241K USD
Liabilities, Current 6.68M USD
Operating Lease, Liability, Noncurrent 1.06M USD
Liabilities 7.73M USD
Retained Earnings (Accumulated Deficit) -32.4M USD
Stockholders' Equity Attributable to Parent 2.74M USD -74%
Liabilities and Equity 10.5M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.28M USD -110%
Net Cash Provided by (Used in) Financing Activities 3.28M USD -77.5%
Net Cash Provided by (Used in) Investing Activities -8K USD +85.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.01M USD -108%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 7.83M USD -27.3%
Interest Paid, Excluding Capitalized Interest, Operating Activities 4K USD
Operating Lease, Liability 1.55M USD
Depreciation 141K USD +192%
Payments to Acquire Property, Plant, and Equipment 8K USD -85.7%
Lessee, Operating Lease, Liability, to be Paid 1.76M USD
Property, Plant and Equipment, Gross 929K USD
Operating Lease, Liability, Current 392K USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 544K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 488K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 210K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 509K USD
Preferred Stock, Shares Authorized 10M shares -90%
Additional Paid in Capital 35.2M USD
Share-based Payment Arrangement, Expense 2.06M USD +30%
Interest Expense 5K USD -50%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares